Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03977194 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Atezolizumab in Elderly Patients With Advanced Non-Small-Cell Lung Cancer and Receiving Carboplatin Paclitaxel Chemotherapy

Study acronym: ELDERLY
StatusActive, Not Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Enrollment target: estimated 500 to confirmed 510v11
  2. Primary completion date changed from estimate of Dec 2024 to Aug 31, 2024v10
  3. Primary completion date: Dec 2023 to Dec 2024 Trial status: Recruiting to Active, Not Recruiting · Study sites: 69 to 68 · Completion date: Apr 2024 to Dec 2026v9 Show 3 more changesShow less
    • Trial status: Recruiting to Active, Not Recruiting
    • Study sites: 69 to 68
    • Completion date: Apr 2024 to Dec 2026
  4. Primary completion date: Aug 2022 to Dec 2023 Completion date: Apr 2023 to Apr 2024v8 Show 1 more changeShow less
    • Completion date: Apr 2023 to Apr 2024
  5. Study sites: 70 to 69 Eligibility criteria expanded, about 22 wordsv7 Show 1 more changeShow less
    • Eligibility criteria expanded, about 22 words

    See this version in full on ClinicalTrials.gov ↗

Show 5 earlier versionsHide 5 earlier versions
  1. Study sites revised (70)v6 See this version in full on ClinicalTrials.gov ↗
  2. Study sites: 65 to 70 Eligibility criteria shortened, about 34 wordsv5 Show 1 more changeShow less
    • Eligibility criteria shortened, about 34 words

    See this version in full on ClinicalTrials.gov ↗

  3. Re-verified, no change to tracked fieldsv4
  4. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Jun 2019 to Jul 23, 2019 · Site details revised at 65 of 65 sites · Publications expanded, about 83 words · 1 morev3 Show 4 more changesShow less
    • Start date changed from estimate of Jun 2019 to Jul 23, 2019
    • Site details revised at 65 of 65 sites
    • Publications expanded, about 83 words
    • Study title shortened, about 5 words

    See this version in full on ClinicalTrials.gov ↗

  5. Study title shortened, about 3 wordsv2 See this version in full on ClinicalTrials.gov ↗
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Non Small Cell Lung Cancer (NSCLC) remains the leading cause of death by cancer in the world. Because of the increase in lung cancer incidence with age and the increase of life expectancy, about half of the patients are patients aged 70 or older. Several clinical trials have shown the interest of adding immunotherapy to standard 1st line chemotherapy in NSCLC. Although in these studies there was not necessarily a higher age limit, in fact the proportion of included patients aged 75 or older remains low (between 7 and 10%). It is therefore necessary to conduct a trial dedicated to these patients in order to determine whether immunotherapy is as effective and tolerated as in the general population.
Trial Details
NCT Number NCT03977194
Lead Sponsor Intergroupe Francophone de Cancerologie Thoracique
Conditions Non Small Cell Lung Cancer Metastatic
Enrollment 510 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov